Last reviewed · How we verify

almotriptan or pseudoephedrine — Competitive Intelligence Brief

almotriptan or pseudoephedrine (almotriptan or pseudoephedrine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan + sympathomimetic decongestant combination. Area: Neurology.

marketed Triptan + sympathomimetic decongestant combination 5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

almotriptan or pseudoephedrine (almotriptan or pseudoephedrine) — Clinvest. This is a combination product containing almotriptan (a selective 5-HT1B/1D receptor agonist for migraine) and pseudoephedrine (a sympathomimetic nasal decongestant).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
almotriptan or pseudoephedrine TARGET almotriptan or pseudoephedrine Clinvest marketed Triptan + sympathomimetic decongestant combination 5-HT1B/1D receptors (almotriptan); alpha-adrenergic receptors (pseudoephedrine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan + sympathomimetic decongestant combination class)

  1. Clinvest · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). almotriptan or pseudoephedrine — Competitive Intelligence Brief. https://druglandscape.com/ci/almotriptan-or-pseudoephedrine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: